Replimune Group, Inc. (REPL)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$20.69+0.19%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · REPL
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 6.1% |
| Our one-year growth estimate | diamond | Not available |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 65 industry peers · Company calendar date is not available
REPL — earnings in line
Dated 2026-08-14
of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly stated by specific reference in such filing.
Why it matters: Moving the RP2 study into Phase 3 would mark progress for its uveal melanoma program. The company has said the study is actively enrolling.
Supportive ifA company update confirms that REVEAL has moved into Phase 3 during Q1 2027.
Worry ifThe company reports that the Phase 3 transition has slipped past Q1 2027, or that REVEAL enrollment has stopped.
Why it matters: The company is funding a new drug launch and clinical trials while reporting losses. A shorter runway could raise financing risk.
Worry ifA later cash update still says available funds cover more than twelve months of operations.
Less concerning ifA later cash update puts runway at twelve months or less, or reports a need for new financing sooner.
Why it matters: This Phase 3 trial must confirm the clinical benefit behind TUDRIQEV's accelerated approval. A delay or pause in enrollment could raise risk.
Worry ifCompany updates say enrollment in IGNYTE-3 is active. They report no pause or delay.
Less concerning ifThe company reports that IGNYTE-3 enrollment is paused, delayed, or no longer on track.
Why it matters: More sites prescribing the drug would show that launch interest is turning into wider use. The release gives no sales figure yet.
Supportive ifA later company update reports more than 15 institutions prescribing TUDRIQEV. The count is rising, and patients continue to use it.
Worry ifA later update shows no growth in prescribing sites, or few patients using it despite broad outreach to accounts.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$239 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $858 loss on $10,000 · 8.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,416 loss on $10,000 · 84.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.